BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer

Sen Zhu, Dongyu Zhao, Chao Li, Qiaqia Li, Weihua Jiang, Qipeng Liu, Rui Wang, Ladan Fazli, Yinan Li, Lili Zhang, Yang Yi, Qingshu Meng, Wanyi Wang, Guangyu Wang, Min Zhang, Xiongbing Zu, Wei Zhao, Tuo Deng, Jindan Yu, Xuesen DongKaifu Chen, Qi Cao*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

B lymphoma Mo-MLV insertion region 1 (BMI1) has been reported to be an oncoprotein. BMI1 represses tumor suppressors to promote cell proliferation, epithelial-mesenchymal transition (EMT), and cancer progression. Although it is known that the expression of BMI1 is increased in many cancer types, the mechanism of BMI1 upregulation is not yet clear. We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1. Next, we showed that dihydrotestosterone (DHT) upregulated both mRNA and protein levels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both human patients and a mouse xenograph model. We further identified an AR binding site in the promoter/enhancer region of BMI1, and confirmed BMI1 as the direct target of AR using gene-editing technology. We also demonstrated that high expression of BMI1 is critical for the development of castration-resistance. Our data also suggest that BMI1-specific inhibitors could be an effective treatment of CRPC.

Original languageEnglish (US)
Pages (from-to)17-29
Number of pages13
JournalOncogene
Volume39
Issue number1
DOIs
StatePublished - Jan 2 2020

Fingerprint

Castration
Androgen Receptors
Lymphoma
Prostatic Neoplasms
Neoplasms
Epithelial-Mesenchymal Transition
Dihydrotestosterone
Oncogene Proteins
Genetic Promoter Regions
Up-Regulation
Binding Sites
Cell Proliferation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Zhu, Sen ; Zhao, Dongyu ; Li, Chao ; Li, Qiaqia ; Jiang, Weihua ; Liu, Qipeng ; Wang, Rui ; Fazli, Ladan ; Li, Yinan ; Zhang, Lili ; Yi, Yang ; Meng, Qingshu ; Wang, Wanyi ; Wang, Guangyu ; Zhang, Min ; Zu, Xiongbing ; Zhao, Wei ; Deng, Tuo ; Yu, Jindan ; Dong, Xuesen ; Chen, Kaifu ; Cao, Qi. / BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. In: Oncogene. 2020 ; Vol. 39, No. 1. pp. 17-29.
@article{70226b620a3d4b85bfae899b187ade3e,
title = "BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer",
abstract = "B lymphoma Mo-MLV insertion region 1 (BMI1) has been reported to be an oncoprotein. BMI1 represses tumor suppressors to promote cell proliferation, epithelial-mesenchymal transition (EMT), and cancer progression. Although it is known that the expression of BMI1 is increased in many cancer types, the mechanism of BMI1 upregulation is not yet clear. We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1. Next, we showed that dihydrotestosterone (DHT) upregulated both mRNA and protein levels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both human patients and a mouse xenograph model. We further identified an AR binding site in the promoter/enhancer region of BMI1, and confirmed BMI1 as the direct target of AR using gene-editing technology. We also demonstrated that high expression of BMI1 is critical for the development of castration-resistance. Our data also suggest that BMI1-specific inhibitors could be an effective treatment of CRPC.",
author = "Sen Zhu and Dongyu Zhao and Chao Li and Qiaqia Li and Weihua Jiang and Qipeng Liu and Rui Wang and Ladan Fazli and Yinan Li and Lili Zhang and Yang Yi and Qingshu Meng and Wanyi Wang and Guangyu Wang and Min Zhang and Xiongbing Zu and Wei Zhao and Tuo Deng and Jindan Yu and Xuesen Dong and Kaifu Chen and Qi Cao",
year = "2020",
month = "1",
day = "2",
doi = "10.1038/s41388-019-0966-4",
language = "English (US)",
volume = "39",
pages = "17--29",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "1",

}

Zhu, S, Zhao, D, Li, C, Li, Q, Jiang, W, Liu, Q, Wang, R, Fazli, L, Li, Y, Zhang, L, Yi, Y, Meng, Q, Wang, W, Wang, G, Zhang, M, Zu, X, Zhao, W, Deng, T, Yu, J, Dong, X, Chen, K & Cao, Q 2020, 'BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer', Oncogene, vol. 39, no. 1, pp. 17-29. https://doi.org/10.1038/s41388-019-0966-4

BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. / Zhu, Sen; Zhao, Dongyu; Li, Chao; Li, Qiaqia; Jiang, Weihua; Liu, Qipeng; Wang, Rui; Fazli, Ladan; Li, Yinan; Zhang, Lili; Yi, Yang; Meng, Qingshu; Wang, Wanyi; Wang, Guangyu; Zhang, Min; Zu, Xiongbing; Zhao, Wei; Deng, Tuo; Yu, Jindan; Dong, Xuesen; Chen, Kaifu; Cao, Qi.

In: Oncogene, Vol. 39, No. 1, 02.01.2020, p. 17-29.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer

AU - Zhu, Sen

AU - Zhao, Dongyu

AU - Li, Chao

AU - Li, Qiaqia

AU - Jiang, Weihua

AU - Liu, Qipeng

AU - Wang, Rui

AU - Fazli, Ladan

AU - Li, Yinan

AU - Zhang, Lili

AU - Yi, Yang

AU - Meng, Qingshu

AU - Wang, Wanyi

AU - Wang, Guangyu

AU - Zhang, Min

AU - Zu, Xiongbing

AU - Zhao, Wei

AU - Deng, Tuo

AU - Yu, Jindan

AU - Dong, Xuesen

AU - Chen, Kaifu

AU - Cao, Qi

PY - 2020/1/2

Y1 - 2020/1/2

N2 - B lymphoma Mo-MLV insertion region 1 (BMI1) has been reported to be an oncoprotein. BMI1 represses tumor suppressors to promote cell proliferation, epithelial-mesenchymal transition (EMT), and cancer progression. Although it is known that the expression of BMI1 is increased in many cancer types, the mechanism of BMI1 upregulation is not yet clear. We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1. Next, we showed that dihydrotestosterone (DHT) upregulated both mRNA and protein levels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both human patients and a mouse xenograph model. We further identified an AR binding site in the promoter/enhancer region of BMI1, and confirmed BMI1 as the direct target of AR using gene-editing technology. We also demonstrated that high expression of BMI1 is critical for the development of castration-resistance. Our data also suggest that BMI1-specific inhibitors could be an effective treatment of CRPC.

AB - B lymphoma Mo-MLV insertion region 1 (BMI1) has been reported to be an oncoprotein. BMI1 represses tumor suppressors to promote cell proliferation, epithelial-mesenchymal transition (EMT), and cancer progression. Although it is known that the expression of BMI1 is increased in many cancer types, the mechanism of BMI1 upregulation is not yet clear. We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1. Next, we showed that dihydrotestosterone (DHT) upregulated both mRNA and protein levels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both human patients and a mouse xenograph model. We further identified an AR binding site in the promoter/enhancer region of BMI1, and confirmed BMI1 as the direct target of AR using gene-editing technology. We also demonstrated that high expression of BMI1 is critical for the development of castration-resistance. Our data also suggest that BMI1-specific inhibitors could be an effective treatment of CRPC.

UR - http://www.scopus.com/inward/record.url?scp=85071948605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071948605&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0966-4

DO - 10.1038/s41388-019-0966-4

M3 - Article

C2 - 31462713

AN - SCOPUS:85071948605

VL - 39

SP - 17

EP - 29

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 1

ER -